Objective :To study the effects of pirarubicin and mitoxantrone for bladder cancer perfusion chemotherapy on the expression of malignant molecules in serum and lavage fluid.Methods :Patients with advanced bladder cancer who under-went bladder cancer perfusion chemotherapy in our hospital between March 2015 and December 2017 were selected and ran-domly divided into the THP group who accepted pirarubicin perfusion chemotherapy and the MTZ group who accepted mitox-antrone perfusion chemotherapy.The serum was collected before and after chemotherapy to determine the contents of tumor markers in serum ;the lavage liquid was collected after chemotherapy to determine the contents of malignant molecules.Re-sults :Compared with those of same group before chemotherapy ,CXCL5 ,VEGF ,CYFRA21-1 ,DKK1 and DKK3 contents in serum of both group of patients decreased chemotherapy ,and CXCL5 ,VEGF ,CYFRA21-1 ,DKK1 and DKK3 contents in se-rum of MTZ group after chemotherapy were lower than those of THP group ;ILP-2 ,CyclinD1 ,Twist ,EpCAM and MMP2 contents in lavage liquid of MTZ group were significantly lower than those of THP group whereas Bad ,Bax ,TRAIL ,FasL , E-cadherin and TIMP4 contents were significantly higher than those of THP group.Conclusion :Mitoxantrone for bladder canc-er perfusion chemotherapy can be more effectively than pirarubicin to regulate the expression of malignant molecules.%目的:研究吡柔比星与米托蒽醌用于膀胱癌灌注化疗对血清及灌洗液中恶性分子表达的影响.方法:选择我院2015年3月～2017年12月期间进行膀胱灌注化疗的晚期膀胱癌患者,随机分为接受吡柔比星灌注化疗的THP组和接受米托蒽醌灌注化疗的MTZ组.化疗前后采集血清并测定肿瘤标志物的含量,化疗后采集灌洗液并测定恶性分子的含量.结果:与组内化疗前比较,两组患者化疗后血清中CXCL5 、VEGF 、CYFRA21-1 、DKK1 、DKK3的含量均呈降低趋势且MTZ组患者化疗后血清中CXCL5 、VEGF 、CYFRA21-1 、DKK1 、DKK3的含量低于THP组;MTZ组患者化疗后灌洗液中ILP-2 、CyclinD1 、Twist 、EpCAM 、MMP2 的含量显著低于 THP 组,Bad 、Bax 、TRAIL 、FasL 、E-cadherin 、TIMP4的显著高于THP组.结论:米托蒽醌用于膀胱癌灌注化疗能够较吡柔比星更为有效的调节恶性分子表达.
展开▼
